Claus Garbe
Impact in
- Oncology top 0.01%
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Dermatology top 0.01%
Papers in
- Oncology 532
- Cutaneous Melanoma Detection and Management 394
- Cancer Immunotherapy and Biomarkers 91
- CAR-T cell therapy research 85
- Dermatology 148
- Cutaneous lymphoproliferative disorders research 68
- Co-authors
- Ulrike Leiter (98 shared papers)Thomas Eigentler (151 shared papers)Axel Hauschild (84 shared papers)Birgit Schittek (48 shared papers)Friedegund Elke Meier (65 shared papers)G. Rassner (53 shared papers)Dirk Schadendorf (70 shared papers)Jürgen M. Bauer (62 shared papers)
- Journals
- European Journal of Cancer (76 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (68 papers)British Journal of Dermatology (36 papers)Melanoma Research (35 papers)Journal of Investigative Dermatology (29 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Claus Garbe
818 papers receiving 63.7k citations
Claus Garbe's Hit Papers
Peers
Comparison fields: 5 of 190
- Oncology 36.5k
- Dermatology 6.3k
- Immunology 11.2k
- Molecular Biology 26.5k
- Cancer Research 3.9k
Countries citing papers authored by Claus Garbe
This map shows the geographic impact of Claus Garbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claus Garbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claus Garbe more than expected).
Fields of papers citing papers by Claus Garbe
This network shows the impact of papers produced by Claus Garbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claus Garbe. The network helps show where Claus Garbe may publish in the future.
Co-authors
The 25 scholars most cited alongside Claus Garbe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 857 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Hit paper breakdown → | 2011 | 6388 |
| 2 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Hit paper breakdown → | 2011 | 3746 |
| 3 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1820 |
| 4 | Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma Hit paper breakdown → | 2014 | 1697 |
| 5 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Hit paper breakdown → | 2014 | 1551 |
| 6 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1225 |
| 7 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial Hit paper breakdown → | 2015 | 1129 |
| 8 | Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Hit paper breakdown → | 2019 | 1048 |
| 9 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Hit paper breakdown → | 2014 | 836 |
| 10 | Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2016 | 827 |
| 11 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2018 | 813 |
| 12 | Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma Hit paper breakdown → | 2013 | 672 |
| 13 | Dermcidin: a novel human antibiotic peptide secreted by sweat glands Hit paper breakdown → | 2001 | 596 |
| 14 | Epidemiology of Melanoma and Nonmelanoma Skin Cancer—The Role of Sunlight Hit paper breakdown → | 2009 | 584 |
| 15 | Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy Hit paper breakdown → | 2016 | 555 |
| 16 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study Hit paper breakdown → | 2017 | 536 |
| 17 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 532 |
| 18 | 2008 | 520 | |
| 19 | Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial Hit paper breakdown → | 2016 | 515 |
| 20 | Melanoma Hit paper breakdown → | 2015 | 497 |
About Claus Garbe
Claus Garbe is a scholar working on Oncology, Dermatology, Immunology, Epidemiology and Molecular Biology, having authored 857 papers that have together received 65.8k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (394 papers), Melanoma and MAPK Pathways (197 papers), Nonmelanoma Skin Cancer Studies (128 papers), Immunotherapy and Immune Responses (110 papers), Cancer Immunotherapy and Biomarkers (91 papers), CAR-T cell therapy research (85 papers), Cutaneous lymphoproliferative disorders research (68 papers) and melanin and skin pigmentation (38 papers). The work is most often cited by research in Oncology (36.5k citations), Dermatology (6.3k citations), Immunology (11.2k citations), Molecular Biology (26.5k citations) and Cancer Research (3.9k citations). Claus Garbe has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Ulrike Leiter, Thomas Eigentler, Axel Hauschild, Birgit Schittek, Friedegund Elke Meier, G. Rassner, Dirk Schadendorf, Jürgen M. Bauer, Helmut Breuninger and Benjamin Weide. Their work appears in journals such as European Journal of Cancer, JDDG Journal der Deutschen Dermatologischen Gesellschaft, British Journal of Dermatology, Melanoma Research and Journal of Investigative Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.